M. Laruelle et al., Dopamine and serotonin transporters in patients with schizophrenia: An imaging study with [I-123]beta-CIT, BIOL PSYCHI, 47(5), 2000, pp. 371-379
Background: Several lines of evidence derived from imaging and postmortem s
tudies suggest that schizophrenia is associated with hyperactivity of dopam
ine function and deficiency in serotonin (5-HT) function. The aim of this s
tudy was to investigate potential alterations of striatal dopamine transpor
ters (DAT) and brainstem serotonin transporters (SERT) density in schizophr
enia.
Methods: Striatal DAT and brainstem SERT were measured in 24 patients with
schizophrenia and 22 matched healthy control subjects using single photon e
mission computed tomography and [I-123]beta-CIT. In this cohort of subjects
, we previously reported an increase in striatal amphetamine-induced dopami
ne release, measured as the displacement of the D-2 receptor radiotracer [I
-123]IBZM.
Results: No differences were observed between patients and control subjects
in the equilibrium uptake ratio (V-3") of [I-123]beta-CIT in the striatum,
indicating that schizophrenia is not generally associated with an alterati
on of striatal DAT density; however a trend level association (p = -.07) wa
s observed in patients with schizophrenia between low striatal [I-123]beta-
CIT V-3" and severity of negative symptoms. After controlling for age, stri
atal [I-123]beta-CIT V-3" in patients was not associated with duration of i
llness, suggesting that this relative deficit was not secondary to a neurod
egenerative process. No correlation was observed between DAT density and am
phetamine-induced dopamine release, either in the patients or in the contro
ls. Brainstem [I-123]beta-CIT V-3" was unaffected in patients with schizoph
renia, and was unrelated to symptomatology.
Conclusions: Schizophrenia is generally not associated with alterations of
DAT in the striatum or SEPT in the brainstem. In some patients, a relative
deficit in dopamine nerve terminals might play a role in the pathophysiolog
y of negative symptoms. (C) 2000 Society of Biological Psychiatry.